Access Dermatology

Breaking News

• Home »
• Breaking News »
• Breaking News article

New guidelines established on the use of intravenous immunoglobulin therapy in dermatology

The European Journal of Dermatology has recently published new guidelines prepared by the European Dermatology Forum Guideline Subcommittee to address the treatment of severe dermatological autoimmune diseases and toxic epidermal necrolysis with high-dose intravenous immunoglobulins (IVIg). The indications addressed in these guidelines include dermatomyositis, autoimmune blistering diseases, vasculitic syndromes, lupus erythematodes and other collagen vascular diseases, and toxic epidermal necrolysis. Other potential indications, for which there is no conclusive evidence available to date, comprise atopic dermatitis, autoimmune urticaria, scleromyxedema and pyoderma gangrenosum. Implementation of these guidelines in the European Union is expected to optimize the use of IVIg therapy throughout Europe (Enk, A. Eur J Dermatol 2009, 19[1]: 90).